Get started
Author

Davide Nappi

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
2021 · Massimo Offidani, Laura Corvatta, et al. · Frontiers in Oncology · 64
PDF
Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study
2018 · Patrizia Mondello, Normann Steiner, et al. · The Oncologist · 40
PDF
Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin
2021 · Michele Gottardi, Giorgia Simonetti, et al. · Cancers · 20
PDF
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials
2023 · Massimo Gentile, Ernesto Vigna, et al. · Haematologica · 19
PDF
Secondary syphilis mimicking malignancy: A case report and review of literature
2017 · Claudio Cerchione, Alberto Enrico Maraolo, et al. · Journal of Infection and Chemotherapy · 19
Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023–2024: EPICOVIDEHA ‐ EPIFLUEHA Report
2024 · Jon Salmanton‐García, Francesco Marchesi, et al. · American Journal of Hematology · 17
Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon
2022 · Massimo Martino, Virginia Naso, et al. · International Journal of Molecular Sciences · 17
PDF
ABVD vs BEACOPP escalated in advanced‐stage Hodgkin’s lymphoma: Results from a multicenter European study
2020 · Patrizia Mondello, Caterina Musolino, et al. · American Journal of Hematology · 17
Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis
2019 · Novella Pugliese, Claudia Giordano, et al. · Cancer Medicine · 12
PDF
Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a patient with primary myelofibrosis
2017 · Claudio Cerchione, Ilaria Peluso, et al. · Annals of Hematology · 12
PDF
Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone
2016 · Claudio Cerchione, Lucio Catalano, et al. · Supportive Care in Cancer · 12
PDF
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients
2025 · E.A. Martino, S. Palmieri, et al. · ESMO Open · 11
PDF
Novel insights and therapeutic approaches in secondary AML
2024 · Giovanni Marconi, Michela Rondoni, et al. · Frontiers in Oncology · 10
PDF
Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
2021 · Claudio Cerchione, Davide Nappi, et al. · Supportive Care in Cancer · 10
PDF
Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies—bendamustine and G-CSF support
2019 · Claudio Cerchione, Amalia De Renzo, et al. · Supportive Care in Cancer · 10
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials
2024 · Enrica Antonia Martino, Salvatore Palmieri, et al. · Hematological Oncology · 7
PDF
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials
2024 · Enrica Antonia Martino, Daniele Derudas, et al. · Haematologica · 6
PDF
Combined Oral Fentanyl Citrate and Midazolam as Premedication for Bone Marrow Aspiration and Biopsy in Patients with Hematological Malignancies: A Randomized, Controlled and Patient-Blinded Clinical Trial
2020 · Claudio Cerchione, Giovanni Martinelli, et al. · Journal of Clinical Medicine · 6
PDF
A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group
2023 · Gregorio Barilà, Francesca Maria Quaglia, et al. · Annals of Hematology · 5
PDF
The power of telemedicine to improve CAR-T cell therapy programs: lessons learned from COVID-19 pandemic
2023 · Filippo A. Canale, Massimo Martino, et al. · Supportive Care in Cancer · 5
PDF
Adding Hydroxyurea in Combination with Ruxolitinib Improves Clinical Responses in Hyperproliferative Forms of Myelofibrosis
2018 · Novella Pugliese, Claudia Giordano, et al. · Blood · 4
Safety and comfort of domestic bortezomib injection in real-life experience
2018 · Claudio Cerchione, Davide Nappi, et al. · Supportive Care in Cancer · 3
A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide
2017 · Claudio Cerchione, Davide Nappi, et al. · Clinical Case Reports · 3
PDF
Beyond the Usual Suspects: RSV Infection in Patients With Hematological Malignancies Compared to Influenza and SARS‐COV‐2—A Report From the EPICOVIDEHA/EPIRESEHA Registry
2025 · Jon Salmanton‐García, Francesco Marchesi, et al. · American Journal of Hematology · 2
PDF
Radiopsy: a prospective observational study on quantitative multiparametric whole-body magnetic resonance imaging to discriminate between smoldering and multiple myeloma
2025 · Giacomo Feliciani, Emiliano Loi, et al. · Haematologica · 2
PDF
Works count: 123
Citation count: 355
H-index: 11
I10-index: 15
Year
Topic
Type